Inhibitors of Aldosterone Synthase.

The mineralocorticoid aldosterone is an important regulator of blood pressure and electrolyte balance. However, excess aldosterone can be deleterious as a driver of inflammation, vascular remodeling and tissue fibrosis associated with cardiometabolic diseases. Mineralocorticoid receptor antagonists (MRA) and renin-angiotensin-aldosterone system (RAAS) antagonists are current clinical therapies used to antagonize deleterious effects of aldosterone in patients. MRAs compete with aldosterone for binding at its cognate receptor thereby limiting its effect while RAS antagonists reduce aldosterone levels indirectly by blocking the stimulatory effect of angiotensin. Both MRAs and RAS antagonists can result in incomplete inhibition of the harmful effects of excess aldosterone. Aldosterone synthase (AS) inhibitors (ASI) attenuate the production of aldosterone directly and have been proposed as an alternative to MRAs and RAS blockers. Cortisol synthase (CS) is an enzyme closely related to AS and responsible for generating the important glucocorticoid cortisol, required for maintaining critical metabolic and immune responses. The importance of selectivity against CS is shown by early examples of ASIs that were only modestly selective and as such, attenuated cortisol responses when evaluated in patients. Recently, next-generation, highly selective ASIs have been described and are presently being evaluated in the clinic as an alternative to angiotensin and MR antagonists for cardiometabolic disease. Herein we provide a brief review of the challenges associated with discovery of selective ASIs and the transition from the early compounds that paved the way toward the next-generation of highly selective ASIs currently under development.

• Publication year

  2019

• Venue

  Vitamins and hormones

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/bs.vh.2018.10.002PMID 30678857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.

  2017cited by this paper
• 4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures.

  2017cited by this paper
• Imidazopyridyl compounds as aldosterone synthase inhibitors.

  2017cited by this paper
• Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity.

  2017cited by this paper
• Pharmacophore Modeling and in Silico/in Vitro Screening for Human Cytochrome P450 11B1 and Cytochrome P450 11B2 Inhibitors

  2017cited by this paper
• LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase

  2017cited by this paper
• A novel aldosterone synthase inhibitor ameliorates mortality in pressure‐overload mice with heart failure

  2017cited by this paper
• Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension.

  2017cited by this paper
• Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association

  2016cited by this paper
• Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.

  2016cited by this paper
• Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)

  2016cited by this paper
• Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2).

  2016cited by this paper
• Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates

  2016cited by this paper
• Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.

  2015cited by this paper
• Dysglycemia and Dyslipidemia Models in Nonhuman Primates: Part I. Model of Naturally Occurring Diabetes

  2015cited by this paper
• Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.

  2015cited by this paper
• 1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.

  2015cited by this paper
• Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

  2015cited by this paper
• Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

  2015cited by this paper
• Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review.

  2015cited by this paper
• Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.

  2015cited by this paper
• Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

  2015cited by this paper
• Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

  2015cited by this paper
• Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.

  2015cited by this paper
• Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.

  2015cited by this paper
• Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

  2015cited by this paper
• Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.

  2015cited by this paper
• Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.

  2014cited by this paper
• Aldosterone synthase inhibitors in cardiovascular and renal diseases.

  2014cited by this paper
• Development of monoclonal antibodies against human CYP11B1 and CYP11B2.

  2014cited by this paper
• Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects

  2014cited by this paper
• LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

  2014cited by this paper
• Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.

  2014cited by this paper
• Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms.

  2013cited by this paper
• Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism

  2013cited by this paper
• Aldosterone synthase inhibition in humans.

  2013cited by this paper
• Progress towards clinically useful aldosterone synthase inhibitors.

  2013cited by this paper
• Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis

  2013cited by this paper
• Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.

  2013cited by this paper
• Vascular effects of aldosterone: Sorting out the receptors and the ligands

  2013cited by this paper
• Evolving research in nongenomic actions of aldosterone

  2013cited by this paper
• Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation.

  2013cited by this paper
• Study of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension

  2013cited by this paper
• Vascular Actions of Aldosterone

  2012cited by this paper
• Acute and chronic regulation of aldosterone production.

  2012cited by this paper
• The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Study

  2012cited by this paper
• uman aldosterone synthase : Recombinant expression in E . coli and purification nables a detailed biochemical analysis of the protein on the molecular level

  2012cited by this paper
• 3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2

  2012cited by this paper
• Non-genomic actions of aldosterone: from receptors and signals to membrane targets.

  2012cited by this paper
• The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension.

  2011cited by this paper
• Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets

  2011cited by this paper
• Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.

  2011cited by this paper
• Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial

  2011cited by this paper
• N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).

  2011cited by this paper
• Cell membrane-associated mineralocorticoid receptors? New evidence.

  2011cited by this paper
• Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis

  2010cited by this paper
• Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).

  2010cited by this paper
• Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease

  2010cited by this paper
• Aldosterone: effects on the kidney and cardiovascular system

  2010cited by this paper
• HORMONAL AND ELECTROLYTE RESPONSES TO THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN SODIUM DEPLETED HEALTHY SUBJECTS

  2010cited by this paper
• Aldosterone and inflammation

  2010cited by this paper
• Pharmacodynamic and Pharmacokinetic Characterization of the Aldosterone Synthase Inhibitor FAD286 in Two Rodent Models of Hyperaldosteronism: Comparison with the 11β-Hydroxylase Inhibitor Metyrapone

  2010cited by this paper
• The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.

  2010cited by this paper
• Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism

  2010cited by this paper
• Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo.

  2009cited by this paper
• New aspects of rapid aldosterone signaling.

  2009cited by this paper
• Aromatase inhibitors: past, present and future in breast cancer therapy

  2008cited by this paper
• Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.

  2008cited by this paper
• In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.

  2008cited by this paper
• Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.

  2008cited by this paper
• Nongenomic Actions of Aldosterone on the Renal Tubule

  2007cited by this paper
• The incidence and implications of aldosterone breakthrough

  2007cited by this paper
• Kidney function in mice lacking aldosterone.

  2006cited by this paper
• Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

  2006cited by this paper
• Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2).

  2006cited by this paper
• Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.

  2006cited by this paper
• Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?

  2006cited by this paper
• Investigation of aldosterone-synthase inhibition in rats

  2006cited by this paper
• Disturbed Homeostasis in Sodium-Restricted Mice Heterozygous and Homozygous for Aldosterone Synthase Gene Disruption

  2006cited by this paper
• Aldosterone and end-organ damage.

  2005cited by this paper
• Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.

  2005cited by this paper
• Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage

  2005cited by this paper
• Aldosterone and end-organ damage

  2005cited by this paper
• Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.

  2005cited by this paper
• The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.

  2005cited by this paper
• Synthesis of Amidinohydrazones and Evaluation of Their Inhibitory Effect towards Aldosterone Synthase (CYP11B2) and the Formation of Selected Steroids

  2004cited by this paper
• The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction

  2004cited by this paper
• Rapid Nongenomic Effects of Aldosterone on Human Forearm Vasculature

  2003cited by this paper
• Aldosterone in chronic kidney and cardiac disease.

  2003cited by this paper
• Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis.

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• The role of the renin-angiotensin system in the development of cardiovascular disease.

  2002cited by this paper
• Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1.

  2002cited by this paper
• Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells.

  2002cited by this paper
• Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology.

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Expression and possible role of muscle-type carnitine palmitoyltransferase I during sperm development in the rat.

  1998cited by this paper
• Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism.

  1998cited by this paper
• Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).

  1996cited by this paper
• The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects.

  1992cited by this paper

• Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases.

  2025cites this paper
• Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease

  2025cites this paper
• Targeting cholesterol-dependent adrenal steroidogenesis for management of primary aldosteronism.

  2025cites this paper
• Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction.

  2024cites this paper
• Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors.

  2024cites this paper
• Aldosterone: Renal Action and Physiological Effects.

  2023cites this paper
• Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention

  2023cites this paper
• Non-Haemodynamic Mechanisms Underlying Hypertension-Associated Damage in Target Kidney Components

  2023cites this paper
• Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks

  2023cites this paper
• Advances in the Pathogenesis and Treatment of Resistant Hypertension

  2023cites this paper
• Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists

  2023cites this paper
• The impact of different diuretics on regression of myocardial reperfusion injury in spontaneously hypertensive rats

  2022cites this paper
• Redox partner adrenodoxin alters cytochrome P450 11B1 ligand binding and inhibition.

  2022cites this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonism for cardiovascular and renal disorders - new perspectives for combination therapy.

  2021cites this paper
• Development of [18F]AldoView as the First Highly Selective Aldosterone Synthase PET Tracer for Imaging of Primary Hyperaldosteronism

  2021cites this paper
• The Type of Fat in the Diet Influences Regulatory Aminopeptidases of the Renin-Angiotensin System and Stress in the Hypothalamic-Pituitary-Adrenal Axis in Adult Wistar Rats

  2021cites this paper
• A patent review of aldosterone synthase inhibitors (2014-present)

  2021cites this paper
• THE ROLE OF ALDOSTERONE INHIBITORS ON CARDIAC ISCHEMIA/REPERFUSION INJURY.

  2020influential citation
• Mitigating risk of aldosterone in diabetic kidney disease

  2019cites this paper